Source link : https://www.newshealth.biz/health-news/nmo-drug-looks-good-for-igg4-related-disease/
WASHINGTON — Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients treated with the drug in the 135-person phase III study developed disease flares during 1 year of follow-up, compared with 60% of a placebo group (P Complete flare-free […]
Author : News Health
Publish date : 2024-11-15 17:13:29
Copyright for syndicated content belongs to the linked Source.